Clinical trial · Observational
Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this registry is to evaluate the situation regarding ambulant therapy of cancer patients in different practices in Germany. It should provide insight into the implementation of schemes for cancer therapy predefined in the guidelines, the treatment of diverse adverse reactions and the counter measures taken. Thereby, potential differences in treatment and with that differences in quality amongst individual practices might be identified. The medium to long term aim is to contribute to positively influence the quality of medical care of cancer patients in Germany.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma | Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Cancer patients
- description
- Patients suffering from a carcinoma (either breast, ovarian, lung, colon, stomach, pancreas, rectum or plasmacytoma)
Primary outcomes (1)
- measure
- Anti-cancer treatments (Course of the disease and type of applied anti-cancer therapies. Assessment of guidelines' implementation)
- timeFrame
- From date of ICF until date of cure/death/ICF withdrawal, up to 60 months
- description
- Course of the disease and type of applied anti-cancer therapies. Assessment of guidelines' implementation
Secondary outcomes (1)
- measure
- Adverse reactions and their treatment (Number and type of adverse reactions and applied counter measures / therapies)
- timeFrame
- From date of ICF until date of cure/death/ICF withdrawal, up to 60 months
- description
- Number and type of adverse reactions and applied counter measures / therapies
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years and older * Tumor disease (carcinoma of either breast, ovary, lung, colon, stomach, pancreas, rectum or plasmacytoma) * Written informed consent Exclusion Criteria: none
References
Publications (0)
Data not yet available